Group 1 - The core announcement indicates that Yongtai Bio-B (06978) has fulfilled or waived all conditions precedent under the subscription agreement [1] - The company has issued new convertible bonds totaling RMB 270 million and notes amounting to RMB 30 million to investors according to the terms and conditions [1] - The proceeds from the subscription are specifically designated for the full and final repayment of the principal amount of the 2023 convertible bonds, which are due on February 20, 2026 [1]

Group 1 - The company Yongtai Bio-B (06978) announced that all conditions precedent under the subscription agreement have been met or waived, if applicable [1] - The company has issued new convertible bonds with a total principal amount of RMB 270 million and notes with a principal amount of RMB 30 million to investors according to the terms and conditions [1] - The proceeds from the subscription will be used exclusively for the full and final repayment of the principal amount of the 2023 convertible bonds, which are due on February 20, 2026 [1]

Group 1 - The core announcement from Yongtai Bio (stock code: 6978) is regarding the financing through the issuance of new convertible bonds and notes, raising a total of approximately 300 million RMB [1] - The total principal amount of the new convertible bonds issued is 270 million RMB, while the principal amount of the notes is 30 million RMB [1] - The initial conversion price for the new convertible bonds is set at 2.92 HKD, representing a premium of about 18.2% over the previous trading day's closing price of 2.47 HKD [1] Group 2 - Upon full conversion, the company will issue 102,880,787 shares, which accounts for approximately 16.7% of the existing issued share capital [1] - The funds raised will be specifically used for the full and final repayment of the principal amount of the 2023 convertible bonds, which are due on February 20, 2026 [1] - The issuance is conducted under the general authorization granted by the shareholders' meeting and is expected to be completed after certain conditions of the subscription agreement are met or waived [1]

Core Viewpoint - Yongtai Bio-B (06978) has announced a conditional agreement to issue new convertible bonds worth RMB 270 million and notes worth RMB 30 million, aimed at repaying existing convertible bonds due on February 20, 2026 [1] Group 1: Convertible Bonds and Notes - The new convertible bonds will have an initial conversion price of HKD 2.92 per share, equivalent to RMB 2.62 [1] - Upon full exercise of the conversion rights attached to the new convertible bonds, a maximum of 103 million shares will be issued, representing approximately 16.66% of the existing issued shares and about 14.28% of the enlarged issued shares after the conversion [1] Group 2: Use of Proceeds - The proceeds from the subscription will be exclusively used for the full and final repayment of the outstanding principal amount of the 2023 convertible bonds [1] Group 3: Conditions and Guarantees - The new convertible bonds and notes will be secured by collateral as outlined in the relevant documentation [1] - Upon receipt of the new convertible bonds and notes, and after the company has paid the accrued unpaid interest on the 2023 convertible bonds, the investors will sign a repayment deed confirming the full and final repayment of the 2023 convertible bonds [1]

Core Viewpoint - Yongtai Bio-B (06978) has announced a conditional agreement to issue new convertible bonds worth RMB 270 million and notes worth RMB 30 million, aimed at repaying existing convertible bonds due on February 20, 2026 [1] Group 1: Convertible Bonds and Notes - The new convertible bonds will have an initial conversion price of HKD 2.92 per share, equivalent to RMB 2.62 [1] - Upon full exercise of the conversion rights attached to the new convertible bonds, a maximum of 103 million shares will be issued, representing approximately 16.66% of the existing issued shares and about 14.28% of the enlarged issued shares after the conversion [1] Group 2: Use of Proceeds - The proceeds from the subscription will be exclusively used for the full and final repayment of the 2023 convertible bonds [1] - The issuance of the new convertible bonds and notes will be secured by collateral as per the relevant documentation [1] Group 3: Conditions and Agreements - The investors are required to sign a repayment deed in favor of the company, confirming the full and final repayment of the 2023 convertible bonds upon receipt of the new convertible bonds and notes [1]

Core Viewpoint - Yongtai Bio-B (06978.HK) has announced a conditional agreement to issue new convertible bonds and notes, aimed at repaying existing convertible bonds due in February 2026 [1] Group 1: Financial Details - The company will issue new convertible bonds amounting to RMB 270 million, with an initial conversion price of HKD 2.92 per share [1] - Additionally, the company will issue notes amounting to RMB 30 million [1] - The proceeds from the issuance will be used exclusively for the full repayment of the 2023 convertible bonds maturing on February 20, 2026 [1] Group 2: Share Issuance Impact - Upon full exercise of the conversion rights attached to the new convertible bonds, a maximum of 102,880,787 shares will be issued, representing approximately 16.66% of the existing issued shares and about 14.28% of the enlarged issued shares post-issuance [1] Group 3: Conditions and Agreements - The issuance of the new convertible bonds and notes is contingent upon the company paying the accrued unpaid interest on the 2023 convertible bonds and fulfilling other specified conditions [1] - Investors are required to sign a repayment deed benefiting the company, confirming the full and final repayment of the 2023 convertible bonds upon receipt of the new bonds and notes [1]

Group 1 - The company Yongtai Biological-B (06978) issued convertible bonds on February 20, 2023, which will mature on February 20, 2026 [1] - A framework agreement was established with investor Jiaze Global Capital Limited, the existing holder of the 2023 convertible bonds, for the subscription of new convertible bonds worth 270 million HKD and notes worth 30 million HKD [1] - The proceeds from the subscription will be used exclusively for the full and final repayment of the principal amount of the 2023 convertible bonds [1] Group 2 - The initial conversion price of the new convertible bonds is set at 2.92 HKD per share, which represents a premium of approximately 5.8% over the last trading price of 2.76 HKD per share on the Hong Kong Stock Exchange [1]

Group 1 - The core announcement is that Yongtai Biological-B (06978.HK) has issued a convertible bond on February 20, 2023, which will mature on February 20, 2026 [1] - The company has entered into a framework agreement with investors, who are existing holders of the 2023 convertible bonds, agreeing to subscribe to new convertible bonds and notes [1] - The proceeds from the subscription will be used exclusively for the full and final repayment of the principal amount of the 2023 convertible bonds [1] Group 2 - The new convertible bonds will amount to RMB 270 million and will have a maturity of 364 days [1] - The framework agreement is legally binding and outlines the principal terms of the new convertible bonds and notes [1] - The parties involved will negotiate and finalize the terms and conditions of the subscription agreement as soon as feasible [1]

Core Viewpoint - Yongtai Bio-B (06978) has issued convertible bonds in 2023, with a framework agreement established for new bond subscriptions to repay existing bonds [1] Group 1: Bond Issuance Details - The 2023 convertible bonds were issued on February 20, 2023, and will mature on February 20, 2026 [1] - A framework agreement was signed with investor Jiaze Global Capital Limited on January 20, 2026, for the subscription of new convertible bonds worth 270 million HKD and notes worth 30 million HKD [1] - The proceeds from the subscription will be used exclusively for the full repayment of the principal amount of the 2023 convertible bonds [1] Group 2: Pricing Information - The initial conversion price for the new convertible bonds is set at 2.92 HKD per share, which is approximately 5.8% higher than the last trading price of 2.76 HKD per share on the Hong Kong Stock Exchange [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, SA Investments, will subscribe to new convertible bonds issued by Suntrust, with a total principal amount of up to 13.511 billion Philippine pesos and a zero coupon rate [1] Group 1: Subscription Agreement Details - The subscription agreement for the new convertible bonds was supplemented with a second agreement, extending the final deadline from April 30, 2025, to August 31, 2025 [1] - Other terms and conditions of the subscription agreement remain unchanged [1] Group 2: Regulatory and Trading Information - Suntrust has applied to the Securities and Exchange Commission for confirmation, which is expected to take an additional approximately four months [1] - The company's shares will be suspended from trading starting February 14, 2024, and will continue to be suspended until all resumption guidelines are met [1]